Novo Nordisk's potential layoffs come as the pharmaceutical major, which has developed the weight-loss drug Wegovy, seeks to reduce costs amid a fierce battle with Eli Lilly for the weight-loss drug ...

(Reuters) -Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and ...

Under the terms of the agreement, Novo Nordisk will obtain exclusive global rights to develop and commercialize zaltenibart across all indications. Omeros is set to receive $340 million in upfront and ...

Novo Nordisk is drawing divided views from Wall Street analysts. Some may be disappointed by the loss of market share to Eli Lilly. Three events could turn sentiment positive in the coming months. The ...

Novo Nordisk is drawing divided views from Wall Street analysts. The HSBC approach, in this case, may be sensible, at least on a risk-reward basis. The nearly 50% drop in Novo Nordisk shares is likely ...

Novo Nordisk plans to cut 9,000 jobs globally, including 5,000 in Denmark, to streamline operations and focus on growth. Increased competition in the GLP-1 medication market, with new oral and ...

After another dismal quarter for Novo Nordisk A/S shares, investors are looking to an experimental treatment of the most common form of dementia to help spark a revival. The Danish drugmaker is ...

Oct 15 (Reuters) - Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab and Omeros (OMER.O), opens new tab have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's ...

Morgan Stanley analyst Thibault Boutherin pointed to slowing momentum in U.S. prescriptions for Novo's flagship GLP-1 drugs, the weight-loss treatment Wegovy and type 2 diabetes therapy Ozempic. He ...

FILE PHOTO: A view shows a Novo Nordisk sign outside their office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, July 14, 2025. REUTERS/Tom Little/File Photo (Reuters) -Novo Nordisk has cut ...

Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too. By Eshe Nelson The success of Novo Nordisk, the ...